PT - JOURNAL ARTICLE AU - Yu, Weijie AU - Zhou, Liwei AU - Li, Chongfei AU - Lu, Zhenwei AU - Chen, Xiaoyu AU - Yu, Hao AU - Chen, Xiaoyan AU - Huang, Qionghui AU - Li, Zhangyu AU - Xiao, Deyong AU - Mei, Yunyun AU - Wang, Zhanxiang TI - Predicting the causal relationship between polyunsaturated fatty acids and cerebral aneurysm risk from a Mendelian randomization study AID - 10.1101/2023.11.15.23298570 DP - 2024 Jan 01 TA - medRxiv PG - 2023.11.15.23298570 4099 - http://medrxiv.org/content/early/2024/09/03/2023.11.15.23298570.short 4100 - http://medrxiv.org/content/early/2024/09/03/2023.11.15.23298570.full AB - Introduction No conclusive evidence for a link between polyunsaturated fatty acids (PUFA) and cerebral aneurysm has been found in observational research. The aim of our study was to determine the causal impact of PUFA on cerebral aneurysm.Methods Two sample Mendelian randomization (MR) was performed using genetic instruments derived from a recent genome wide association study (GWAS) of fatty acids from UK Biobank and outcome data obtained from the large-scale cerebral aneurysm GWASs in European ancestry which include IA, aneurysmal subarachnoid hemorrhage (aSAH) and unruptured intracranial aneurysm (uIA). Sensitivity analyses were implemented with MVMR, MR-Egger intercept test, MR-PRESSO, leave-one-out analysis and so on. Bayesian colocalization (COLOC) methods was conducted to focus on the association between the fatty acid gene expression and cerebral aneurysm.Results Genetically predicted assessed omega-3 fatty acids decreased the risk for IA (OR = 0.80, 95% CI: 0.69 - 0.91, P = 1.01ⅹ10-3) and aSAH (OR = 0.71, 95% CI: 0.61 - 0.84, P = 3.73ⅹ10-5). Furthermore, the Docosahexaenoic acid decreased the risk for IA (OR = 0.75, 95% CI: 0.63 - 0.87, P = 3.12ⅹ10-4) and aSAH (OR = 0.67, 95% CI: 0.55 - 0.8, P = 2.32ⅹ10-5). The same results were discovered from ratio of omega-3 fatty acids to total fatty acids. While the ratio of omega-6 fatty acids to omega-3 fatty acids increased the risk of IA (OR = 1.27, 95% CI: 1.12 – 1.44, P = 1.53ⅹ10-4) and aSAH (OR = 1.35, 95% CI: 1.17 – 1.56, P = 5.78ⅹ10-5). The result of the COLOC suggested that the above four kinds of fatty acids and IA, aSAH likely share causal variants in gene fatty acid desaturase 2, separately.Conclusion This study utilized integrative analysis of MR and colocalization to discover causal relationships between genetic variants, PUFA and cerebral aneurysm.Funding This study was funded by the Natural Science Foundation of China (82072777), the Natural Science Foundation of Xiamen (3502Z20227097), Fujian Provincial Health Commission, Provincial Health and Health Young and Middle-aged Backbone Talent Training Project (2022GGB010).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Natural Science Foundation of China (82072777), the Natural Science Foundation of Xiamen (3502Z20227097), Fujian Provincial Health Commission, Provincial Health and Health Young and Middle-aged Backbone Talent Training Project (2022GGB010).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://gwas.mrcieu.ac.uk/datasets/met-d-Omega_3/ https://gwas.mrcieu.ac.uk/datasets/met-d-Omega_3_pct/ https://gwas.mrcieu.ac.uk/datasets/met-d-Omega_6_by_Omega_3/ https://gwas.mrcieu.ac.uk/datasets/met-d-DHA/ https://gwas.mrcieu.ac.uk/datasets/met-d-Omega_6/ http://www.cerebrovascularportal.org. https://r8.finngen.fi/pheno/I9_ANEURYSMhttps://www.nature.com/articles/ng.2797I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe GWAS databases we use are all from publicly published data, each of the original GWASs had obtained ethical approval and participant consent